ID   FES_HUMAN               Reviewed;         822 AA.
AC   P07332; B2R6E6; B4DUD0; E9PC94; E9PC95; Q2VXS7; Q2VXS8; Q2VXT0; Q6GTU5;
DT   01-APR-1988, integrated into UniProtKB/Swiss-Prot.
DT   03-OCT-2006, sequence version 3.
DT   12-OCT-2022, entry version 230.
DE   RecName: Full=Tyrosine-protein kinase Fes/Fps;
DE            EC=2.7.10.2;
DE   AltName: Full=Feline sarcoma/Fujinami avian sarcoma oncogene homolog;
DE   AltName: Full=Proto-oncogene c-Fes;
DE   AltName: Full=Proto-oncogene c-Fps;
DE   AltName: Full=p93c-fes;
GN   Name=FES; Synonyms=FPS;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=2179816;
RA   Alcalay M., Antolini F., van de Ven W.J.M., Lanfrancone L., Grignani F.,
RA   Pelicci P.G.;
RT   "Characterization of human and mouse c-fes cDNA clones and identification
RT   of the 5' end of the gene.";
RL   Oncogene 5:267-275(1990).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORM 1).
RX   PubMed=4065096; DOI=10.1002/j.1460-2075.1985.tb04020.x;
RA   Roebroek A.J.M., Schalken J.A., Verbeek J.S., van den Ouweland A.M.W.,
RA   Onnekink C., Bloemers H.P.J., van de Ven W.J.M.;
RT   "The structure of the human c-fes/fps proto-oncogene.";
RL   EMBO J. 4:2897-2903(1985).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 2; 3 AND 4).
RA   Lefebvre J.-C.;
RL   Submitted (DEC-2003) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2).
RC   TISSUE=Tongue;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16572171; DOI=10.1038/nature04601;
RA   Zody M.C., Garber M., Sharpe T., Young S.K., Rowen L., O'Neill K.,
RA   Whittaker C.A., Kamal M., Chang J.L., Cuomo C.A., Dewar K.,
RA   FitzGerald M.G., Kodira C.D., Madan A., Qin S., Yang X., Abbasi N.,
RA   Abouelleil A., Arachchi H.M., Baradarani L., Birditt B., Bloom S.,
RA   Bloom T., Borowsky M.L., Burke J., Butler J., Cook A., DeArellano K.,
RA   DeCaprio D., Dorris L. III, Dors M., Eichler E.E., Engels R., Fahey J.,
RA   Fleetwood P., Friedman C., Gearin G., Hall J.L., Hensley G., Johnson E.,
RA   Jones C., Kamat A., Kaur A., Locke D.P., Madan A., Munson G., Jaffe D.B.,
RA   Lui A., Macdonald P., Mauceli E., Naylor J.W., Nesbitt R., Nicol R.,
RA   O'Leary S.B., Ratcliffe A., Rounsley S., She X., Sneddon K.M.B.,
RA   Stewart S., Sougnez C., Stone S.M., Topham K., Vincent D., Wang S.,
RA   Zimmer A.R., Birren B.W., Hood L., Lander E.S., Nusbaum C.;
RT   "Analysis of the DNA sequence and duplication history of human chromosome
RT   15.";
RL   Nature 440:671-675(2006).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   FUNCTION IN CELL DIFFERENTIATION AND AS TUMOR SUPPRESSOR, AND CATALYTIC
RP   ACTIVITY.
RX   PubMed=2656706; DOI=10.1016/s0021-9258(18)81796-3;
RA   Yu G., Smithgall T.E., Glazer R.I.;
RT   "K562 leukemia cells transfected with the human c-fes gene acquire the
RT   ability to undergo myeloid differentiation.";
RL   J. Biol. Chem. 264:10276-10281(1989).
RN   [9]
RP   PHOSPHORYLATION AT TYR-713, CATALYTIC ACTIVITY, AND MUTAGENESIS OF TYR-713.
RX   PubMed=7687763;
RA   Hjermstad S.J., Peters K.L., Briggs S.D., Glazer R.I., Smithgall T.E.;
RT   "Regulation of the human c-fes protein tyrosine kinase (p93c-fes) by its
RT   src homology 2 domain and major autophosphorylation site (Tyr-713).";
RL   Oncogene 8:2283-2292(1993).
RN   [10]
RP   FUNCTION IN PHOSPHORYLATION OF BCR, AUTOPHOSPHORYLATION, AND ACTIVITY
RP   REGULATION.
RX   PubMed=8955135; DOI=10.1074/jbc.271.51.32930;
RA   Li J., Smithgall T.E.;
RT   "Co-expression with BCR induces activation of the FES tyrosine kinase and
RT   phosphorylation of specific N-terminal BCR tyrosine residues.";
RL   J. Biol. Chem. 271:32930-32936(1996).
RN   [11]
RP   SUBCELLULAR LOCATION.
RX   PubMed=11339827; DOI=10.1006/excr.2001.5217;
RA   Zirngibl R., Schulze D., Mirski S.E., Cole S.P., Greer P.A.;
RT   "Subcellular localization analysis of the closely related Fps/Fes and Fer
RT   protein-tyrosine kinases suggests a distinct role for Fps/Fes in vesicular
RT   trafficking.";
RL   Exp. Cell Res. 266:87-94(2001).
RN   [12]
RP   FUNCTION IN CELL PROLIFERATION AND CELL SPREADING, CATALYTIC ACTIVITY,
RP   AUTOPHOSPHORYLATION, SUBUNIT, DOMAIN, AND MUTAGENESIS OF LEU-145 AND
RP   LEU-334.
RX   PubMed=11509660; DOI=10.1128/mcb.21.18.6170-6180.2001;
RA   Cheng H.Y., Schiavone A.P., Smithgall T.E.;
RT   "A point mutation in the N-terminal coiled-coil domain releases c-Fes
RT   tyrosine kinase activity and survival signaling in myeloid leukemia
RT   cells.";
RL   Mol. Cell. Biol. 21:6170-6180(2001).
RN   [13]
RP   REVIEW.
RX   PubMed=11994747; DOI=10.1038/nrm783;
RA   Greer P.;
RT   "Closing in on the biological functions of Fps/Fes and Fer.";
RL   Nat. Rev. Mol. Cell Biol. 3:278-289(2002).
RN   [14]
RP   FUNCTION IN REORGANIZATION OF THE ACTIN CYTOSKELETON AND CELL
RP   DIFFERENTIATION, AND INTERACTION WITH BCR.
RX   PubMed=15302586; DOI=10.1016/j.yexcr.2004.05.010;
RA   Laurent C.E., Smithgall T.E.;
RT   "The c-Fes tyrosine kinase cooperates with the breakpoint cluster region
RT   protein (Bcr) to induce neurite extension in a Rac- and Cdc42-dependent
RT   manner.";
RL   Exp. Cell Res. 299:188-198(2004).
RN   [15]
RP   FUNCTION, CATALYTIC ACTIVITY, INTERACTION WITH TUBULIN AND MICROTUBULES,
RP   SUBCELLULAR LOCATION, PHOSPHORYLATION AT TYR-713, PHOSPHORYLATION BY HCK,
RP   AND MUTAGENESIS OF LEU-145; ARG-483 AND LYS-590.
RX   PubMed=15485904; DOI=10.1128/mcb.24.21.9351-9358.2004;
RA   Laurent C.E., Delfino F.J., Cheng H.Y., Smithgall T.E.;
RT   "The human c-Fes tyrosine kinase binds tubulin and microtubules through
RT   separate domains and promotes microtubule assembly.";
RL   Mol. Cell. Biol. 24:9351-9358(2004).
RN   [16]
RP   CATALYTIC ACTIVITY, AUTOPHOSPHORYLATION, AND MUTAGENESIS OF MET-704;
RP   ARG-706; VAL-743 AND SER-759.
RX   PubMed=15867340; DOI=10.1158/0008-5472.can-04-3468;
RA   Sangrar W., Zirgnibl R.A., Gao Y., Muller W.J., Jia Z., Greer P.A.;
RT   "An identity crisis for fps/fes: oncogene or tumor suppressor?";
RL   Cancer Res. 65:3518-3522(2005).
RN   [17]
RP   ALTERNATIVE SPLICING.
RX   PubMed=15869408; DOI=10.1089/dna.2005.24.311;
RA   Carlson A., Berkowitz J.M., Browning D., Slamon D.J., Gasson J.C.,
RA   Yates K.E.;
RT   "Expression of c-Fes protein isoforms correlates with differentiation in
RT   myeloid leukemias.";
RL   DNA Cell Biol. 24:311-316(2005).
RN   [18]
RP   INTERACTION WITH TRIM28.
RX   PubMed=16792528; DOI=10.1042/bj20060194;
RA   Delfino F.J., Shaffer J.M., Smithgall T.E.;
RT   "The KRAB-associated co-repressor KAP-1 is a coiled-coil binding partner,
RT   substrate and activator of the c-Fes protein tyrosine kinase.";
RL   Biochem. J. 399:141-150(2006).
RN   [19]
RP   FUNCTION IN STAT3 PHOSPHORYLATION, ROLE AS PUTATIVE TUMOR SUPPRESSOR IN
RP   COLON CANCER, MUTAGENESIS OF MET-704; ARG-706; VAL-743 AND SER-759,
RP   SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RX   PubMed=16455651; DOI=10.1074/jbc.m507331200;
RA   Delfino F.J., Stevenson H., Smithgall T.E.;
RT   "A growth-suppressive function for the c-fes protein-tyrosine kinase in
RT   colorectal cancer.";
RL   J. Biol. Chem. 281:8829-8835(2006).
RN   [20]
RP   FUNCTION IN KIT SIGNALING, AND POSSIBLE ROLE IN CANCER CELL PROLIFERATION.
RX   PubMed=17595334; DOI=10.1182/blood-2007-02-076471;
RA   Voisset E., Lopez S., Dubreuil P., De Sepulveda P.;
RT   "The tyrosine kinase FES is an essential effector of KITD816V proliferation
RT   signal.";
RL   Blood 110:2593-2599(2007).
RN   [21]
RP   FUNCTION IN CYTOSKELETON REORGANIZATION, INTERACTION WITH EZR,
RP   PHOSPHORYLATION AT TYR-713, AND SUBCELLULAR LOCATION.
RX   PubMed=18046454; DOI=10.1038/sj.emboj.7601943;
RA   Naba A., Reverdy C., Louvard D., Arpin M.;
RT   "Spatial recruitment and activation of the Fes kinase by ezrin promotes
RT   HGF-induced cell scattering.";
RL   EMBO J. 27:38-50(2008).
RN   [22]
RP   SUBUNIT, SUBCELLULAR LOCATION, PHOSPHORYLATION AT TYR-713, PHOSPHORYLATION
RP   BY HCK, AND DOMAIN.
RX   PubMed=19382747; DOI=10.1021/bi900238f;
RA   Shaffer J.M., Hellwig S., Smithgall T.E.;
RT   "Bimolecular fluorescence complementation demonstrates that the c-Fes
RT   protein-tyrosine kinase forms constitutive oligomers in living cells.";
RL   Biochemistry 48:4780-4788(2009).
RN   [23]
RP   FUNCTION, TISSUE SPECIFICITY, AND ROLE AS PUTATIVE TUMOR SUPPRESSOR IN
RP   COLON CANCER.
RX   PubMed=19051325; DOI=10.1002/gcc.20638;
RA   Shaffer J.M., Smithgall T.E.;
RT   "Promoter methylation blocks FES protein-tyrosine kinase gene expression in
RT   colorectal cancer.";
RL   Genes Chromosomes Cancer 48:272-284(2009).
RN   [24]
RP   PUTATIVE ROLE IN RENAL CARCINOMA.
RX   PubMed=19082481;
RA   Kanda S., Miyata Y., Kanetake H., Smithgall T.E.;
RT   "Downregulation of the c-Fes protein-tyrosine kinase inhibits the
RT   proliferation of human renal carcinoma cells.";
RL   Int. J. Oncol. 34:89-96(2009).
RN   [25]
RP   FUNCTION, INTERACTION WITH MS4A2/FCER1B AND HCLS1/HS1, SUBCELLULAR
RP   LOCATION, PHOSPHORYLATION, INTERACTION WITH PHOSPHOINOSITIDE-CONTAINING
RP   MEMBRANES, AND MUTAGENESIS OF 113-ARG-LYS-114.
RX   PubMed=19001085; DOI=10.1128/mcb.00904-08;
RA   McPherson V.A., Everingham S., Karisch R., Smith J.A., Udell C.M.,
RA   Zheng J., Jia Z., Craig A.W.;
RT   "Contributions of F-BAR and SH2 domains of Fes protein tyrosine kinase for
RT   coupling to the FcepsilonRI pathway in mast cells.";
RL   Mol. Cell. Biol. 29:389-401(2009).
RN   [26]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-64; SER-67; TYR-261; TYR-713
RP   AND SER-716, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [27]
RP   FUNCTION, PHOSPHORYLATION AT THR-421, AND INTERACTION WITH FLT3.
RX   PubMed=20111072; DOI=10.1038/leu.2009.301;
RA   Voisset E., Lopez S., Chaix A., Georges C., Hanssens K., Prebet T.,
RA   Dubreuil P., De Sepulveda P.;
RT   "FES kinases are required for oncogenic FLT3 signaling.";
RL   Leukemia 24:721-728(2010).
RN   [28]
RP   REVIEW.
RX   PubMed=21622225; DOI=10.2741/3902;
RA   Hellwig S., Smithgall T.E.;
RT   "Structure and regulation of the c-Fes protein-tyrosine kinase.";
RL   Front. Biosci. 16:3146-3155(2011).
RN   [29]
RP   POSSIBLE ROLE IN PROSTATE CANCER.
RX   PubMed=21563194; DOI=10.1002/pros.21422;
RA   Miyata Y., Watanabe S.I., Matsuo T., Hayashi T., Sakai H., Xuan J.W.,
RA   Greer P.A., Kanda S.;
RT   "Pathological significance and predictive value for biochemical recurrence
RT   of c-Fes expression in prostate cancer.";
RL   Prostate 72:201-208(2012).
RN   [30]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-408 AND SER-411, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [31]
RP   TISSUE SPECIFICITY, ROLE AS TUMOR SUPPRESSOR IN MELANOMA, AND MUTAGENESIS
RP   OF LYS-590.
RX   PubMed=28463229; DOI=10.1172/jci91291;
RA   Olvedy M., Tisserand J.C., Luciani F., Boeckx B., Wouters J., Lopez S.,
RA   Rambow F., Aibar S., Thienpont B., Barra J., Koehler C., Radaelli E.,
RA   Tartare-Deckert S., Aerts S., Dubreuil P., van den Oord J.J.,
RA   Lambrechts D., De Sepulveda P., Marine J.C.;
RT   "Comparative oncogenomics identifies tyrosine kinase FES as a tumor
RT   suppressor in melanoma.";
RL   J. Clin. Invest. 127:2310-2325(2017).
RN   [32]
RP   STRUCTURE BY NMR OF 450-550.
RX   PubMed=15929003; DOI=10.1007/s10858-005-0946-6;
RA   Scott A., Pantoja-Uceda D., Koshiba S., Inoue M., Kigawa T., Terada T.,
RA   Shirouzu M., Tanaka A., Sugano S., Yokoyama S., Guentert P.;
RT   "Solution structure of the Src homology 2 domain from the human feline
RT   sarcoma oncogene Fes.";
RL   J. Biomol. NMR 31:357-361(2005).
RN   [33]
RP   X-RAY CRYSTALLOGRAPHY (1.78 ANGSTROMS) OF 448-822 OF UNPHOSPHORYLATED
RP   APOPROTEIN AND IN COMPLEX WITH STAUROSPORINE AND A SUBSTRATE PEPTIDE,
RP   CATALYTIC ACTIVITY, ACTIVITY REGULATION, PHOSPHORYLATION AT TYR-713, NMR
RP   SPECTROSCOPY, AND MUTAGENESIS OF GLY-463 AND ARG-483.
RX   PubMed=18775312; DOI=10.1016/j.cell.2008.07.047;
RA   Filippakopoulos P., Kofler M., Hantschel O., Gish G.D., Grebien F.,
RA   Salah E., Neudecker P., Kay L.E., Turk B.E., Superti-Furga G., Pawson T.,
RA   Knapp S.;
RT   "Structural coupling of SH2-kinase domains links Fes and Abl substrate
RT   recognition and kinase activation.";
RL   Cell 134:793-803(2008).
RN   [34]
RP   VARIANTS [LARGE SCALE ANALYSIS] CYS-85; GLN-246 AND VAL-323.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Tyrosine-protein kinase that acts downstream of cell surface
CC       receptors and plays a role in the regulation of the actin cytoskeleton,
CC       microtubule assembly, cell attachment and cell spreading. Plays a role
CC       in FCER1 (high affinity immunoglobulin epsilon receptor)-mediated
CC       signaling in mast cells. Acts down-stream of the activated FCER1
CC       receptor and the mast/stem cell growth factor receptor KIT. Plays a
CC       role in the regulation of mast cell degranulation. Plays a role in the
CC       regulation of cell differentiation and promotes neurite outgrowth in
CC       response to NGF signaling. Plays a role in cell scattering and cell
CC       migration in response to HGF-induced activation of EZR. Phosphorylates
CC       BCR and down-regulates BCR kinase activity. Phosphorylates HCLS1/HS1,
CC       PECAM1, STAT3 and TRIM28. {ECO:0000269|PubMed:11509660,
CC       ECO:0000269|PubMed:15302586, ECO:0000269|PubMed:15485904,
CC       ECO:0000269|PubMed:16455651, ECO:0000269|PubMed:17595334,
CC       ECO:0000269|PubMed:18046454, ECO:0000269|PubMed:19001085,
CC       ECO:0000269|PubMed:19051325, ECO:0000269|PubMed:20111072,
CC       ECO:0000269|PubMed:2656706, ECO:0000269|PubMed:8955135}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-tyrosyl-[protein] = ADP + H(+) + O-phospho-L-tyrosyl-
CC         [protein]; Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA-
CC         COMP:10137, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858,
CC         ChEBI:CHEBI:82620, ChEBI:CHEBI:456216; EC=2.7.10.2;
CC         Evidence={ECO:0000255|PROSITE-ProRule:PRU10028,
CC         ECO:0000269|PubMed:11509660, ECO:0000269|PubMed:15485904,
CC         ECO:0000269|PubMed:15867340, ECO:0000269|PubMed:18775312,
CC         ECO:0000269|PubMed:2656706, ECO:0000269|PubMed:7687763};
CC   -!- ACTIVITY REGULATION: Kinase activity is tightly regulated. Activated in
CC       response to signaling from a cell surface receptor. Activation probably
CC       requires binding of a substrate via the SH2 domain, plus
CC       autophosphorylation at Tyr-713. Present in an inactive form in the
CC       absence of activating stimuli. {ECO:0000269|PubMed:18775312,
CC       ECO:0000269|PubMed:8955135}.
CC   -!- SUBUNIT: Homooligomer. Interacts with BCR. Interacts (when activated,
CC       via coiled coil domain) with TRIM28. Interacts (via SH2 domain) with
CC       phosphorylated EZR, MS4A2/FCER1B and HCLS1/HS1. Interacts with
CC       phosphorylated KIT. Interacts with FLT3. Interacts (via F-BAR domain)
CC       with soluble tubulin. Interacts (via SH2 domain) with microtubules.
CC       {ECO:0000269|PubMed:11509660, ECO:0000269|PubMed:15302586,
CC       ECO:0000269|PubMed:15485904, ECO:0000269|PubMed:16792528,
CC       ECO:0000269|PubMed:18046454, ECO:0000269|PubMed:18775312,
CC       ECO:0000269|PubMed:19001085, ECO:0000269|PubMed:19382747,
CC       ECO:0000269|PubMed:20111072}.
CC   -!- INTERACTION:
CC       P07332; P10275: AR; NbExp=3; IntAct=EBI-1055635, EBI-608057;
CC       P07332; P15924: DSP; NbExp=2; IntAct=EBI-1055635, EBI-355041;
CC       P07332; P15311: EZR; NbExp=8; IntAct=EBI-1055635, EBI-1056902;
CC       P07332; Q13480: GAB1; NbExp=2; IntAct=EBI-1055635, EBI-517684;
CC       P07332; P10721: KIT; NbExp=2; IntAct=EBI-1055635, EBI-1379503;
CC       P07332; P54274: TERF1; NbExp=2; IntAct=EBI-1055635, EBI-710997;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm, cytosol. Cytoplasm, cytoskeleton. Cell
CC       membrane; Peripheral membrane protein; Cytoplasmic side. Cytoplasmic
CC       vesicle. Golgi apparatus. Cell junction, focal adhesion.
CC       Note=Distributed throughout the cytosol when the kinase is not
CC       activated. Association with microtubules requires activation of the
CC       kinase activity. Shuttles between focal adhesions and cell-cell
CC       contacts in epithelial cells. Recruited to the lateral cell membrane in
CC       polarized epithelial cells by interaction with phosphorylated EZR.
CC       Detected at tubular membrane structures in the cytoplasm and at the
CC       cell periphery.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC       Name=1;
CC         IsoId=P07332-1; Sequence=Displayed;
CC       Name=2; Synonyms=Variant 1;
CC         IsoId=P07332-2; Sequence=VSP_041748, VSP_041749;
CC       Name=3; Synonyms=Variant 3;
CC         IsoId=P07332-3; Sequence=VSP_041748;
CC       Name=4; Synonyms=Variant 4;
CC         IsoId=P07332-4; Sequence=VSP_041749;
CC   -!- TISSUE SPECIFICITY: Widely expressed. Detected in adult colon
CC       epithelium (at protein level) (PubMed:16455651, PubMed:19051325).
CC       Expressed in melanocytes (at protein level) (PubMed:28463229).
CC       {ECO:0000269|PubMed:16455651, ECO:0000269|PubMed:19051325,
CC       ECO:0000269|PubMed:28463229}.
CC   -!- DOMAIN: The coiled coil domains are important for regulating the kinase
CC       activity. They mediate homooligomerization and probably also
CC       interaction with other proteins.
CC   -!- DOMAIN: The N-terminal region including the first coiled coil domain
CC       mediates interaction with phosphoinositide-containing membranes.
CC   -!- PTM: Autophosphorylated on Tyr-713. Phosphorylated by LYN in response
CC       to FCER1 activation. Phosphorylated by HCK.
CC       {ECO:0000269|PubMed:15485904, ECO:0000269|PubMed:18046454,
CC       ECO:0000269|PubMed:18775312, ECO:0000269|PubMed:19001085,
CC       ECO:0000269|PubMed:19382747, ECO:0000269|PubMed:20111072,
CC       ECO:0000269|PubMed:7687763}.
CC   -!- DISEASE: Note=Has been shown to act as proto-oncogene in some types of
CC       cancer, possibly due to abnormal activation of the kinase. Has been
CC       shown to act as tumor suppressor in other types of cancer. Expressed
CC       and present as activated kinase in a subset of acute myeloid leukemia
CC       patients; promotes survival of leukemia cells (PubMed:20111072).
CC       Expression is absent in K562 leukemia cells; ectopic expression of
CC       FSP/FES restores myeloid differentiation (PubMed:2656706). May function
CC       as tumor suppressor in colorectal cancer; expression is reduced or
CC       absent in samples from some colon cancer patients (PubMed:16455651).
CC       May function as tumor suppressor in melanoma by preventing melanoma
CC       cell proliferation; expression is reduced or absent in samples from
CC       some melanoma patients (PubMed:28463229). Ectopic expression of FSP/FES
CC       suppresses anchorage-independent growth in colon cancer cell lines
CC       (PubMed:16455651). Up-regulated in prostate cancer, and might be a
CC       predictor of recurrence after radical surgery (PubMed:16455651). May
CC       promote growth of renal carcinoma cells (PubMed:19082481).
CC       {ECO:0000269|PubMed:16455651, ECO:0000269|PubMed:19082481,
CC       ECO:0000269|PubMed:20111072, ECO:0000269|PubMed:2656706,
CC       ECO:0000269|PubMed:28463229}.
CC   -!- MISCELLANEOUS: Cellular homolog of retroviral oncogenes. In contrast to
CC       the viral oncoproteins, the kinase activity of cellular FSP/FES is
CC       tightly regulated, and the kinase is inactive in normal cells in the
CC       absence of activating stimuli (PubMed:15485904).
CC       {ECO:0000305|PubMed:15485904}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. Fes/fps subfamily. {ECO:0000255|PROSITE-
CC       ProRule:PRU00159}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; X52192; CAA36438.1; -; mRNA.
DR   EMBL; X06292; CAA29619.1; -; Genomic_DNA.
DR   EMBL; AY513654; AAS82866.1; -; mRNA.
DR   EMBL; AY513656; AAS82868.1; -; mRNA.
DR   EMBL; AY513657; AAS82869.1; -; mRNA.
DR   EMBL; AK300595; BAG62292.1; -; mRNA.
DR   EMBL; AK312545; BAG35443.1; -; mRNA.
DR   EMBL; AC124248; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471101; EAX02114.1; -; Genomic_DNA.
DR   EMBL; BC035357; AAH35357.1; -; mRNA.
DR   CCDS; CCDS10365.1; -. [P07332-1]
DR   CCDS; CCDS45349.1; -. [P07332-4]
DR   CCDS; CCDS45350.1; -. [P07332-3]
DR   CCDS; CCDS45351.1; -. [P07332-2]
DR   PIR; A24673; TVHUFF.
DR   RefSeq; NP_001137255.1; NM_001143783.1. [P07332-3]
DR   RefSeq; NP_001137256.1; NM_001143784.1. [P07332-4]
DR   RefSeq; NP_001137257.1; NM_001143785.1. [P07332-2]
DR   RefSeq; NP_001996.1; NM_002005.3. [P07332-1]
DR   RefSeq; XP_005254937.1; XM_005254880.1. [P07332-3]
DR   RefSeq; XP_005254939.1; XM_005254882.1. [P07332-4]
DR   RefSeq; XP_016877494.1; XM_017022005.1. [P07332-1]
DR   RefSeq; XP_016877495.1; XM_017022006.1. [P07332-3]
DR   RefSeq; XP_016877496.1; XM_017022007.1. [P07332-4]
DR   RefSeq; XP_016877497.1; XM_017022008.1. [P07332-2]
DR   RefSeq; XP_016877498.1; XM_017022009.1. [P07332-1]
DR   RefSeq; XP_016877499.1; XM_017022010.1. [P07332-3]
DR   PDB; 1WQU; NMR; -; A=450-550.
DR   PDB; 2DCR; NMR; -; A=450-550.
DR   PDB; 3BKB; X-ray; 1.78 A; A=448-822.
DR   PDB; 3CBL; X-ray; 1.75 A; A=448-822.
DR   PDB; 3CD3; X-ray; 1.98 A; A=448-822.
DR   PDB; 4DYL; X-ray; 2.18 A; A=1-405.
DR   PDB; 4E93; X-ray; 1.84 A; A=448-822.
DR   PDB; 6JMF; X-ray; 2.00 A; A=449-822.
DR   PDBsum; 1WQU; -.
DR   PDBsum; 2DCR; -.
DR   PDBsum; 3BKB; -.
DR   PDBsum; 3CBL; -.
DR   PDBsum; 3CD3; -.
DR   PDBsum; 4DYL; -.
DR   PDBsum; 4E93; -.
DR   PDBsum; 6JMF; -.
DR   AlphaFoldDB; P07332; -.
DR   BMRB; P07332; -.
DR   SMR; P07332; -.
DR   BioGRID; 108533; 32.
DR   IntAct; P07332; 36.
DR   MINT; P07332; -.
DR   STRING; 9606.ENSP00000331504; -.
DR   BindingDB; P07332; -.
DR   ChEMBL; CHEMBL5455; -.
DR   DrugBank; DB12010; Fostamatinib.
DR   DrugCentral; P07332; -.
DR   GuidetoPHARMACOLOGY; 2023; -.
DR   iPTMnet; P07332; -.
DR   PhosphoSitePlus; P07332; -.
DR   BioMuta; FES; -.
DR   DMDM; 115502390; -.
DR   CPTAC; CPTAC-1778; -.
DR   EPD; P07332; -.
DR   jPOST; P07332; -.
DR   MassIVE; P07332; -.
DR   MaxQB; P07332; -.
DR   PaxDb; P07332; -.
DR   PeptideAtlas; P07332; -.
DR   PRIDE; P07332; -.
DR   ProteomicsDB; 51989; -. [P07332-1]
DR   ProteomicsDB; 51990; -. [P07332-2]
DR   ProteomicsDB; 51991; -. [P07332-3]
DR   ProteomicsDB; 51992; -. [P07332-4]
DR   Antibodypedia; 734; 469 antibodies from 34 providers.
DR   DNASU; 2242; -.
DR   Ensembl; ENST00000328850.8; ENSP00000331504.3; ENSG00000182511.12. [P07332-1]
DR   Ensembl; ENST00000394300.7; ENSP00000377837.3; ENSG00000182511.12. [P07332-3]
DR   Ensembl; ENST00000414248.6; ENSP00000414629.2; ENSG00000182511.12. [P07332-2]
DR   Ensembl; ENST00000444422.2; ENSP00000400868.2; ENSG00000182511.12. [P07332-4]
DR   GeneID; 2242; -.
DR   KEGG; hsa:2242; -.
DR   MANE-Select; ENST00000328850.8; ENSP00000331504.3; NM_002005.4; NP_001996.1.
DR   UCSC; uc002bpv.4; human. [P07332-1]
DR   CTD; 2242; -.
DR   DisGeNET; 2242; -.
DR   GeneCards; FES; -.
DR   HGNC; HGNC:3657; FES.
DR   HPA; ENSG00000182511; Tissue enhanced (bone marrow, lymphoid tissue).
DR   MIM; 190030; gene.
DR   neXtProt; NX_P07332; -.
DR   OpenTargets; ENSG00000182511; -.
DR   PharmGKB; PA28098; -.
DR   VEuPathDB; HostDB:ENSG00000182511; -.
DR   eggNOG; KOG0194; Eukaryota.
DR   GeneTree; ENSGT00940000158881; -.
DR   HOGENOM; CLU_005265_0_1_1; -.
DR   InParanoid; P07332; -.
DR   OMA; RAKDKYV; -.
DR   PhylomeDB; P07332; -.
DR   TreeFam; TF315363; -.
DR   BRENDA; 2.7.10.2; 2681.
DR   PathwayCommons; P07332; -.
DR   Reactome; R-HSA-1433557; Signaling by SCF-KIT.
DR   Reactome; R-HSA-399954; Sema3A PAK dependent Axon repulsion.
DR   Reactome; R-HSA-399955; SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion.
DR   Reactome; R-HSA-399956; CRMPs in Sema3A signaling.
DR   SignaLink; P07332; -.
DR   SIGNOR; P07332; -.
DR   BioGRID-ORCS; 2242; 15 hits in 1099 CRISPR screens.
DR   ChiTaRS; FES; human.
DR   EvolutionaryTrace; P07332; -.
DR   GeneWiki; Feline_sarcoma_oncogene; -.
DR   GenomeRNAi; 2242; -.
DR   Pharos; P07332; Tclin.
DR   PRO; PR:P07332; -.
DR   Proteomes; UP000005640; Chromosome 15.
DR   RNAct; P07332; protein.
DR   Bgee; ENSG00000182511; Expressed in monocyte and 100 other tissues.
DR   ExpressionAtlas; P07332; baseline and differential.
DR   Genevisible; P07332; HS.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0031410; C:cytoplasmic vesicle; IEA:UniProtKB-KW.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0031234; C:extrinsic component of cytoplasmic side of plasma membrane; IDA:UniProtKB.
DR   GO; GO:0005925; C:focal adhesion; IDA:UniProtKB.
DR   GO; GO:0005794; C:Golgi apparatus; IEA:UniProtKB-SubCell.
DR   GO; GO:0015630; C:microtubule cytoskeleton; IDA:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0034987; F:immunoglobulin receptor binding; IDA:UniProtKB.
DR   GO; GO:0008017; F:microtubule binding; IEA:Ensembl.
DR   GO; GO:0004715; F:non-membrane spanning protein tyrosine kinase activity; IDA:UniProtKB.
DR   GO; GO:0035091; F:phosphatidylinositol binding; IDA:UniProtKB.
DR   GO; GO:0004713; F:protein tyrosine kinase activity; IDA:UniProtKB.
DR   GO; GO:0005102; F:signaling receptor binding; IBA:GO_Central.
DR   GO; GO:0060038; P:cardiac muscle cell proliferation; IEA:Ensembl.
DR   GO; GO:0007155; P:cell adhesion; IBA:GO_Central.
DR   GO; GO:0030154; P:cell differentiation; IBA:GO_Central.
DR   GO; GO:0071305; P:cellular response to vitamin D; IMP:ARUK-UCL.
DR   GO; GO:0007098; P:centrosome cycle; IEA:Ensembl.
DR   GO; GO:0006935; P:chemotaxis; IBA:GO_Central.
DR   GO; GO:0045087; P:innate immune response; IBA:GO_Central.
DR   GO; GO:0001578; P:microtubule bundle formation; IEA:Ensembl.
DR   GO; GO:0051450; P:myoblast proliferation; IEA:Ensembl.
DR   GO; GO:0018108; P:peptidyl-tyrosine phosphorylation; IDA:UniProtKB.
DR   GO; GO:2000251; P:positive regulation of actin cytoskeleton reorganization; IMP:UniProtKB.
DR   GO; GO:0031116; P:positive regulation of microtubule polymerization; IMP:UniProtKB.
DR   GO; GO:0045657; P:positive regulation of monocyte differentiation; IMP:ARUK-UCL.
DR   GO; GO:0045639; P:positive regulation of myeloid cell differentiation; IMP:UniProtKB.
DR   GO; GO:0010976; P:positive regulation of neuron projection development; IMP:UniProtKB.
DR   GO; GO:0046777; P:protein autophosphorylation; IDA:UniProtKB.
DR   GO; GO:0030155; P:regulation of cell adhesion; IMP:UniProtKB.
DR   GO; GO:0045595; P:regulation of cell differentiation; IMP:UniProtKB.
DR   GO; GO:2000145; P:regulation of cell motility; IMP:UniProtKB.
DR   GO; GO:0042127; P:regulation of cell population proliferation; IMP:UniProtKB.
DR   GO; GO:0008360; P:regulation of cell shape; IMP:UniProtKB.
DR   GO; GO:0043304; P:regulation of mast cell degranulation; IMP:UniProtKB.
DR   GO; GO:0060627; P:regulation of vesicle-mediated transport; TAS:UniProtKB.
DR   GO; GO:0007169; P:transmembrane receptor protein tyrosine kinase signaling pathway; IBA:GO_Central.
DR   CDD; cd10361; SH2_Fps_family; 1.
DR   Gene3D; 1.20.1270.60; -; 1.
DR   Gene3D; 3.30.505.10; -; 1.
DR   InterPro; IPR027267; AH/BAR_dom_sf.
DR   InterPro; IPR031160; F_BAR.
DR   InterPro; IPR001060; FCH_dom.
DR   InterPro; IPR035849; Fes/Fps/Fer_SH2.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR000980; SH2.
DR   InterPro; IPR036860; SH2_dom_sf.
DR   InterPro; IPR016250; Tyr-prot_kinase_Fes/Fps.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   InterPro; IPR020635; Tyr_kinase_cat_dom.
DR   Pfam; PF00611; FCH; 1.
DR   Pfam; PF07714; PK_Tyr_Ser-Thr; 1.
DR   Pfam; PF00017; SH2; 1.
DR   PIRSF; PIRSF000632; TyrPK_fps; 1.
DR   PRINTS; PR00401; SH2DOMAIN.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00055; FCH; 1.
DR   SMART; SM00252; SH2; 1.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF103657; SSF103657; 1.
DR   SUPFAM; SSF55550; SSF55550; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS51741; F_BAR; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
DR   PROSITE; PS50001; SH2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; Cell junction;
KW   Cell membrane; Coiled coil; Cytoplasm; Cytoplasmic vesicle; Cytoskeleton;
KW   Golgi apparatus; Kinase; Lipid-binding; Membrane; Nucleotide-binding;
KW   Phosphoprotein; Proto-oncogene; Reference proteome; SH2 domain;
KW   Transferase; Tumor suppressor; Tyrosine-protein kinase.
FT   CHAIN           1..822
FT                   /note="Tyrosine-protein kinase Fes/Fps"
FT                   /id="PRO_0000088088"
FT   DOMAIN          1..260
FT                   /note="F-BAR"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01077"
FT   DOMAIN          460..549
FT                   /note="SH2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00191"
FT   DOMAIN          561..822
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   REGION          1..300
FT                   /note="Important for interaction with membranes containing
FT                   phosphoinositides"
FT   REGION          394..421
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COILED          125..169
FT                   /evidence="ECO:0000255"
FT   COILED          324..368
FT                   /evidence="ECO:0000255"
FT   ACT_SITE        683
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
FT                   ECO:0000255|PROSITE-ProRule:PRU10028"
FT   BINDING         567..575
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         590
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   MOD_RES         64
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:19369195"
FT   MOD_RES         67
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:19369195"
FT   MOD_RES         261
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0007744|PubMed:19369195"
FT   MOD_RES         408
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:24275569"
FT   MOD_RES         411
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:24275569"
FT   MOD_RES         421
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000269|PubMed:20111072"
FT   MOD_RES         713
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:15485904,
FT                   ECO:0000269|PubMed:18046454, ECO:0000269|PubMed:18775312,
FT                   ECO:0000269|PubMed:19382747, ECO:0000269|PubMed:7687763,
FT                   ECO:0007744|PubMed:19369195"
FT   MOD_RES         716
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:19369195"
FT   VAR_SEQ         72..129
FT                   /note="Missing (in isoform 2 and isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:14702039, ECO:0000303|Ref.3"
FT                   /id="VSP_041748"
FT   VAR_SEQ         441..510
FT                   /note="Missing (in isoform 2 and isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:14702039, ECO:0000303|Ref.3"
FT                   /id="VSP_041749"
FT   VARIANT         85
FT                   /note="R -> C (in dbSNP:rs56041861)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041697"
FT   VARIANT         246
FT                   /note="R -> Q (in dbSNP:rs34573430)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041698"
FT   VARIANT         323
FT                   /note="M -> V (in dbSNP:rs56296062)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041699"
FT   MUTAGEN         113..114
FT                   /note="RK->EE: Reduced binding to membranes containing
FT                   phosphoinositides."
FT                   /evidence="ECO:0000269|PubMed:19001085"
FT   MUTAGEN         113..114
FT                   /note="RK->QQ: Reduced binding to membranes containing
FT                   phosphoinositides."
FT                   /evidence="ECO:0000269|PubMed:19001085"
FT   MUTAGEN         145
FT                   /note="L->P: Constitutively activated kinase that can act
FT                   as oncogene. Promotes myeloid cell survival and
FT                   proliferation."
FT                   /evidence="ECO:0000269|PubMed:11509660,
FT                   ECO:0000269|PubMed:15485904"
FT   MUTAGEN         334
FT                   /note="L->P: Abolishes autophosphorylation."
FT                   /evidence="ECO:0000269|PubMed:11509660"
FT   MUTAGEN         463
FT                   /note="G->V: Abolishes kinase activity."
FT                   /evidence="ECO:0000269|PubMed:18775312"
FT   MUTAGEN         483
FT                   /note="R->M: Abolishes pTyr binding. Abolishes association
FT                   with microtubules. Abolishes autophosphorylation. Reduced
FT                   kinase activity."
FT                   /evidence="ECO:0000269|PubMed:15485904,
FT                   ECO:0000269|PubMed:18775312"
FT   MUTAGEN         590
FT                   /note="K->E: Abolishes kinase activity. Fails to inhibit
FT                   proliferation of melanoma cells."
FT                   /evidence="ECO:0000269|PubMed:15485904,
FT                   ECO:0000269|PubMed:28463229"
FT   MUTAGEN         704
FT                   /note="M->V: Reduced autophosphorylation and strongly
FT                   reduced kinase activity."
FT                   /evidence="ECO:0000269|PubMed:15867340,
FT                   ECO:0000269|PubMed:16455651"
FT   MUTAGEN         706
FT                   /note="R->Q: Negligible effect on autophosphorylation and
FT                   kinase activity."
FT                   /evidence="ECO:0000269|PubMed:15867340,
FT                   ECO:0000269|PubMed:16455651"
FT   MUTAGEN         713
FT                   /note="Y->F: Reduces kinase activity by over 90%."
FT                   /evidence="ECO:0000269|PubMed:7687763"
FT   MUTAGEN         743
FT                   /note="V->M: Strongly reduced autophosphorylation and
FT                   kinase activity."
FT                   /evidence="ECO:0000269|PubMed:15867340,
FT                   ECO:0000269|PubMed:16455651"
FT   MUTAGEN         759
FT                   /note="S->F: Reduced autophosphorylation and strongly
FT                   reduced kinase activity."
FT                   /evidence="ECO:0000269|PubMed:15867340,
FT                   ECO:0000269|PubMed:16455651"
FT   CONFLICT        719
FT                   /note="L -> S (in Ref. 1; CAA36438 and 3;
FT                   AAS82866/AAS82869/AAS82868)"
FT                   /evidence="ECO:0000305"
FT   HELIX           3..6
FT                   /evidence="ECO:0007829|PDB:4DYL"
FT   HELIX           10..51
FT                   /evidence="ECO:0007829|PDB:4DYL"
FT   HELIX           68..96
FT                   /evidence="ECO:0007829|PDB:4DYL"
FT   HELIX           98..131
FT                   /evidence="ECO:0007829|PDB:4DYL"
FT   HELIX           133..154
FT                   /evidence="ECO:0007829|PDB:4DYL"
FT   HELIX           167..202
FT                   /evidence="ECO:0007829|PDB:4DYL"
FT   HELIX           204..234
FT                   /evidence="ECO:0007829|PDB:4DYL"
FT   STRAND          236..238
FT                   /evidence="ECO:0007829|PDB:4DYL"
FT   HELIX           239..254
FT                   /evidence="ECO:0007829|PDB:4DYL"
FT   HELIX           257..259
FT                   /evidence="ECO:0007829|PDB:4DYL"
FT   HELIX           262..268
FT                   /evidence="ECO:0007829|PDB:4DYL"
FT   TURN            300..302
FT                   /evidence="ECO:0007829|PDB:4DYL"
FT   HELIX           303..344
FT                   /evidence="ECO:0007829|PDB:4DYL"
FT   HELIX           350..353
FT                   /evidence="ECO:0007829|PDB:4DYL"
FT   HELIX           354..389
FT                   /evidence="ECO:0007829|PDB:4DYL"
FT   TURN            390..393
FT                   /evidence="ECO:0007829|PDB:4DYL"
FT   HELIX           450..452
FT                   /evidence="ECO:0007829|PDB:3CBL"
FT   HELIX           455..457
FT                   /evidence="ECO:0007829|PDB:3CBL"
FT   STRAND          461..464
FT                   /evidence="ECO:0007829|PDB:1WQU"
FT   HELIX           467..473
FT                   /evidence="ECO:0007829|PDB:3CBL"
FT   STRAND          479..484
FT                   /evidence="ECO:0007829|PDB:3CBL"
FT   TURN            486..489
FT                   /evidence="ECO:0007829|PDB:3BKB"
FT   STRAND          491..494
FT                   /evidence="ECO:0007829|PDB:3CBL"
FT   STRAND          503..506
FT                   /evidence="ECO:0007829|PDB:3CBL"
FT   STRAND          507..509
FT                   /evidence="ECO:0007829|PDB:3BKB"
FT   STRAND          512..517
FT                   /evidence="ECO:0007829|PDB:3BKB"
FT   STRAND          520..522
FT                   /evidence="ECO:0007829|PDB:3BKB"
FT   HELIX           523..533
FT                   /evidence="ECO:0007829|PDB:3CBL"
FT   TURN            539..541
FT                   /evidence="ECO:0007829|PDB:3BKB"
FT   HELIX           558..560
FT                   /evidence="ECO:0007829|PDB:3CBL"
FT   STRAND          561..570
FT                   /evidence="ECO:0007829|PDB:3CBL"
FT   STRAND          573..580
FT                   /evidence="ECO:0007829|PDB:3CBL"
FT   TURN            581..583
FT                   /evidence="ECO:0007829|PDB:3CBL"
FT   STRAND          586..591
FT                   /evidence="ECO:0007829|PDB:3CBL"
FT   HELIX           598..601
FT                   /evidence="ECO:0007829|PDB:3CBL"
FT   HELIX           602..605
FT                   /evidence="ECO:0007829|PDB:3CBL"
FT   HELIX           606..611
FT                   /evidence="ECO:0007829|PDB:3CBL"
FT   STRAND          622..626
FT                   /evidence="ECO:0007829|PDB:3CBL"
FT   STRAND          628..631
FT                   /evidence="ECO:0007829|PDB:3CBL"
FT   STRAND          633..637
FT                   /evidence="ECO:0007829|PDB:3CBL"
FT   HELIX           644..651
FT                   /evidence="ECO:0007829|PDB:3CBL"
FT   HELIX           652..654
FT                   /evidence="ECO:0007829|PDB:3CBL"
FT   HELIX           657..676
FT                   /evidence="ECO:0007829|PDB:3CBL"
FT   HELIX           686..688
FT                   /evidence="ECO:0007829|PDB:3CBL"
FT   STRAND          689..691
FT                   /evidence="ECO:0007829|PDB:3CBL"
FT   STRAND          697..699
FT                   /evidence="ECO:0007829|PDB:3CBL"
FT   HELIX           702..704
FT                   /evidence="ECO:0007829|PDB:3CBL"
FT   STRAND          711..714
FT                   /evidence="ECO:0007829|PDB:3CBL"
FT   STRAND          720..723
FT                   /evidence="ECO:0007829|PDB:3CBL"
FT   HELIX           724..726
FT                   /evidence="ECO:0007829|PDB:3CBL"
FT   HELIX           729..734
FT                   /evidence="ECO:0007829|PDB:3CBL"
FT   STRAND          736..738
FT                   /evidence="ECO:0007829|PDB:3CBL"
FT   HELIX           739..754
FT                   /evidence="ECO:0007829|PDB:3CBL"
FT   TURN            755..757
FT                   /evidence="ECO:0007829|PDB:4E93"
FT   HELIX           766..774
FT                   /evidence="ECO:0007829|PDB:3CBL"
FT   HELIX           787..796
FT                   /evidence="ECO:0007829|PDB:3CBL"
FT   HELIX           801..803
FT                   /evidence="ECO:0007829|PDB:3CBL"
FT   HELIX           807..820
FT                   /evidence="ECO:0007829|PDB:3CBL"
SQ   SEQUENCE   822 AA;  93497 MW;  4C2A90555857F045 CRC64;
     MGFSSELCSP QGHGVLQQMQ EAELRLLEGM RKWMAQRVKS DREYAGLLHH MSLQDSGGQS
     RAISPDSPIS QSWAEITSQT EGLSRLLRQH AEDLNSGPLS KLSLLIRERQ QLRKTYSEQW
     QQLQQELTKT HSQDIEKLKS QYRALARDSA QAKRKYQEAS KDKDRDKAKD KYVRSLWKLF
     AHHNRYVLGV RAAQLHHQHH HQLLLPGLLR SLQDLHEEMA CILKEILQEY LEISSLVQDE
     VVAIHREMAA AAARIQPEAE YQGFLRQYGS APDVPPCVTF DESLLEEGEP LEPGELQLNE
     LTVESVQHTL TSVTDELAVA TEMVFRRQEM VTQLQQELRN EEENTHPRER VQLLGKRQVL
     QEALQGLQVA LCSQAKLQAQ QELLQTKLEH LGPGEPPPVL LLQDDRHSTS SSEQEREGGR
     TPTLEILKSH ISGIFRPKFS LPPPLQLIPE VQKPLHEQLW YHGAIPRAEV AELLVHSGDF
     LVRESQGKQE YVLSVLWDGL PRHFIIQSLD NLYRLEGEGF PSIPLLIDHL LSTQQPLTKK
     SGVVLHRAVP KDKWVLNHED LVLGEQIGRG NFGEVFSGRL RADNTLVAVK SCRETLPPDL
     KAKFLQEARI LKQYSHPNIV RLIGVCTQKQ PIYIVMELVQ GGDFLTFLRT EGARLRVKTL
     LQMVGDAAAG MEYLESKCCI HRDLAARNCL VTEKNVLKIS DFGMSREEAD GVYAASGGLR
     QVPVKWTAPE ALNYGRYSSE SDVWSFGILL WETFSLGASP YPNLSNQQTR EFVEKGGRLP
     CPELCPDAVF RLMEQCWAYE PGQRPSFSTI YQELQSIRKR HR
//
